Enlivex (ENLV) Enterprise Value (2013 - 2025)
Enlivex (ENLV) posted quarterly Enterprise Value of -$5.8 million for Q4 2025, up 75.51% year-over-year from -$3.3 million in Q4 2024, and down 130.0% quarter-over-quarter from $19.2 million in Q3 2025.
Enlivex (ENLV) Enterprise Value (2013 - 2025) Analysis & Trends
Enlivex's Enterprise Value history runs 13 years deep, the most recent figure standing at -$5.8 million for Q4 2025.
- In Q4 2025, Enterprise Value rose 75.51% year-over-year to -$5.8 million; the TTM figure through Dec 2025 stood at -$5.8 million (up 75.51% YoY), while the FY2025 annual figure was -$5.8 million, down 119.8% from the prior year.
- Enterprise Value for Q4 2025 stood at -$5.8 million, down from $19.2 million in the prior quarter.
- The five-year high for Enterprise Value was $30.8 million in Q2 2023, with the low at -$78.0 million in Q1 2022.
- The 5-year median for Enterprise Value is -$22.8 million (2021), against an average of -$22.4 million.
- Peak annual rise in Enterprise Value reached 149.04% in 2023, while the deepest fall reached 378.43% in 2023.
- Enlivex's Enterprise Value stood at -$69.9 million in 2021, then jumped by 83.79% to -$11.3 million in 2022, then tumbled by 378.43% to -$54.2 million in 2023, then soared by 56.68% to -$23.5 million in 2024, then soared by 75.51% to -$5.8 million in 2025.
- Business Quant data shows ENLV's Enterprise Value at -$5.8 million in Q4 2025, $19.2 million in Q3 2025, and -$19.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Enlivex | 4.58 Mn | -1.17 Mn | - | -5.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.76 Mn |
| Sep 30, 2025 | 19.19 Mn |
| Jun 30, 2025 | -19.51 Mn |
| Mar 31, 2025 | -20.55 Mn |
| Dec 31, 2024 | -23.50 Mn |
| Sep 30, 2024 | 28.45 Mn |
| Jun 30, 2024 | -25.94 Mn |
| Mar 31, 2024 | -23.44 Mn |
| Dec 31, 2023 | -54.24 Mn |
| Sep 30, 2023 | 28.27 Mn |
| Jun 30, 2023 | 30.76 Mn |
| Mar 31, 2023 | 18.05 Mn |
| Dec 31, 2022 | -11.34 Mn |
| Sep 30, 2022 | -57.66 Mn |
| Jun 30, 2022 | -62.88 Mn |
| Mar 31, 2022 | -78.00 Mn |
| Dec 31, 2021 | -69.94 Mn |
| Sep 30, 2021 | -22.15 Mn |
| Jun 30, 2021 | -23.61 Mn |
| Mar 31, 2021 | -73.23 Mn |